Non-small cell lung cancer
Conditions
Interventions
Four cycle of gemcitabine and platinum-doublet followed by maintenance gemcitabine in 21-days cycle until progression disease
Sponsors
Hiroshima University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or cytologically confirmed squamous non-small cell lung cancer 2) Patients who have measurable lesion 3) Stage III/VI without any indications for radiotherapy, or recurrent disease after surgery 4) Patients aged from 20 older 5)ECOG PS 0-1 6) Adequate organ function, evaluated within 14 days before enrollment (registration day is day1, and on the same day two weeks ago, is impossible) as WBC >= 4,000/mm3 Plt >= 100,000/mm3 Hb >= 9 g/dL AST/ALT <=100IU/L T.Bil <= 1.5 g/dL Ccr >=60mL/min, sCr: x 1.2 of upper limit of normal or less. SpO2 >= 60torr as room air 7) Patients are excepted to live over 3 months after administration day 8)Written informed consent from the patients
Exclusion criteria
Exclusion criteria: (1) Patient having clear infection (2) Patient having hepatitis B with the activity (3) Serious complications (stroma-related pneumonia, bleeding tendency, control are poor a heart trouble, pulmonary fibrosis) The patient whom high blood pressure or diabetes have) (4) Patient having an active overlap cancer (under nondisease period five years) (5) Metastasis to brain patient having a symptom (6) Hydrothorax to need treatment, abdominal dropsy retention patient (7) Pericardial fluid retention patient (8) Patient having an anamnesis of drug allergies (9) A pregnant woman, a nursing girl and woman with the possibility (intention) of the pregnancy (10) principal investigator cases that are deemed inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival | — |
Countries
Japan
Contacts
Public ContactKazunori Fujitaka
Hiroshima University Hospital Depatment of Respiratory Medicine
Outcome results
None listed